… and ALI/ARDS, hoping to contribute to identifying potential … was collected and stored at −
80 ℃ for future analysis. … Epithelial GPR116 was reported to control surfactant secretion and …

… Therefore, the treatment of ALI/ARDS requires the development of a … Therefore, during the
acute inflammatory phase of ALI/ARDS, … This hypothesis will be validated in our future studies. …

… (COVID-2019), still ongoing at the time that this review is being … avenues for targeted therapy
of ALI/ARDS for several reasons. … be considered for future phase I clinical trials in humans. …

… respiratory distress and surfactant PG hydrolysis when … a significant role in the development
of ALI/ARDS [34]. Patients … in human illnesses may be targetable with future study. It's safe to …

… to diagnose high-altitude ALI/ARDS. The clinical criteria include the … Our study found that
surfactant protein D has a protective … in treatment methods between patients living at high or low …

… , surfactants, corticosteroids, antimicrobial treatment and use of … CT-scan at different times
post-MSCs therapy in the ARDS … therapy for the treatment of acute lung diseases in the future. …

… surfactant into the plasma, leading to it is expression at a low level in alveolar lavage fluid
(119). Pulmonary surfactant … effective therapeutic drugs and methods will emerge in the future, …

… treatment of ALI/ARDS, glucocorticoids have been used for many years as they reduce
inflammation and fibrosis through … We believe that the findings of this study will contribute to future …

… Finally, we conclude by discussing the future perspectives … Besides, the alveolar space is
covered by a layer of surfactant (… only help to ameliorate ALI/ARDS symptoms, mainly attributed …

… -specific proteins released during this phase may … during the fibroproliferative phase in
the absence of recovery, and ultimately results in altered lung structure and function in ALI/ARDS …